06:27 AM EST, 01/13/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) is in talks to acquire Intra-Cellular Therapies (ITCI), Bloomberg News reported Sunday, citing unnamed people familiar with the matter.

An agreement for an acquisition could be reached as early as this week but the discussions also fall apart and other buyers may emerge, the report said, citing the sources.

Intra-Cellular Therapies develops drugs for mental health disorders and neurological conditions.

Johnson & Johnson ( JNJ ) and Intra-Cellular Therapies did not immediately reply to MT Newswires' request for comment.

Shares of Intra-Cellular were up more than 32% in Monday's premarket activity.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)